Navigation Links
Vaccine With Drug Payload Shows Promise Against Tumors
Date:2/11/2013

By Randy Dotinga
HealthDay Reporter

MONDAY, Feb. 11 (HealthDay News) -- Preliminary research produced promising results for a cancer-fighting drug that piggybacks on a virus similar to the one used in the smallpox vaccine.

Patients with advanced liver cancer who were given higher doses of the drug lived months longer than those who took lower doses, and the researchers said some of them are still alive three years later.

There are many caveats. The drug, known as JX-594, is in the early stages of development, and the evidence is years from being ready to be submitted for approval by U.S. Food and Drug Administration officials. The study is also very small, doesn't compare patients who took the drug to those who didn't, and offers no details about its potential cost.

However, the finding is unusual because it suggests that a drug that enters the body through a virus can improve survival in cancer patients, said study co-author Dr. David Kirn, chief medical officer with Jennerex Biotherapeutics, in San Francisco, which is developing the medication. The average survival "more than doubled" in those who took the larger doses. "It's exciting and important for the field, but there's no question we need to confirm it," he said.

William Phelps, director of preclinical and translational cancer research for the American Cancer Society, called the research "promising" and said it reflects the evolution of cancer research toward developing new ways to treat the disease other than the traditional methods of surgery, chemotherapy and radiation, which aim to remove or kill the cancer.

The new drug, like others that are now in development, tries to stimulate the patient's own immune system to fight the cancer. It works by entering the body through an "engineered vaccine" that's similar to the vaccine that prevents smallpox. (The vaccine in this case, like the smallpox vaccine, doesn't cause disease.)

Instead of multiplying in regular cells, the virus in this case only multiplies in cancer cells, study co-author Kirn explained. "It makes thousands of copies and bursts the cancer cell," he said, and then releases a kind of alert to the immune system that tells it that other cancer cells need to be destroyed.

In the new study, the second of three phases required in medical research, scientists gave doses of medication to 30 patients with severe liver cancer. They received three doses, injected into the blood or into their tumors, over a month.

Those who took a higher dose lived for 14 months on average, compared to seven months for those who took the lower dose. The researchers reported that the drug appeared to have an effect not only on the liver tumors but also in cancer cells that had spread elsewhere in the body.

While the study is "by no means definitive" overall, that's good news, said Dr. Neal Meropol, chair of the division of hematology and oncology at Case Western University and the Seidman Cancer Center at University Hospitals, in Cleveland.

As for side effects, patients all felt like they had the flu for about a day, Kirn said. About one-third of those who took the higher dose developed anorexia.

Kirn said the research will continue. He declined to provide a specific estimate of how much the drug will cost, but he did say that its production is not "exceedingly expensive."

The study appears online in the Feb. 10 issue of the journal Nature Medicine.

More information

For more about cancer, visit the U.S. National Library of Medicine.

SOURCES: David Kirn, M.D., president, research and development, and founder and chief medical officer, Jennerex Biotherapeutics, San Francisco; Neal Meropol, M.D., chair, division of hematology and oncology, Seidman Cancer Center, University Hospitals, and Case Western University, Cleveland; William Phelps, Ph.D., director, preclinical and translational cancer research, American Cancer Society, Atlanta; Feb. 10, 2013, Nature Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Young girls more likely to report side effects after HPV vaccine
3. Preteens More Likely to Report HPV Vaccine Side Effects
4. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
5. Early Study Finds Some Promise for Lung Cancer Vaccine
6. From a Failed Vaccine, New Insights Into Fighting HIV
7. From herd immunity and complacency to group panic: How vaccine scares unfold
8. Brain Tumor Vaccine Shows Promise in Early Trial
9. Army researcher develops potential vaccine carrier
10. A physicians guide for anti-vaccine parents
11. Shingles Vaccine Safe, Underutilized, Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine With Drug Payload Shows Promise Against Tumors 
(Date:5/6/2016)... ... May 06, 2016 , ... ... scheduled to provide a unique keynote address at the 2016 Learning Summit ... stories of five community college students. Their stories—of complicated family issues, financial difficulties, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate humidity ... is too cold, dry or hot, water on the eye surface can evaporate, creating ... the surrounding air. There’s only one problem, according to radio show and water advocate ...
(Date:5/6/2016)... ... May 06, 2016 , ... From the Speaker Podium ... Technology will share its insights on managing Customers Engagement at SpeechTek 2016 Event, ... 2016, Presence Technology will deliver a Presentation on “5 Customer Engagement Strategies ...
(Date:5/6/2016)... ... May 06, 2016 , ... Expert mattress researchers and ... launching in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com . The move ... sheets, mattress toppers, bed frames, and more. , Founder and Editor-in-Chief Derek Hales ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... , May 6, 2016 ... Molecular Imaging and its Application to Drug Development Including ... Alacrita , the life sciences consulting firm, today ... PhD, as an Associate Partner in its ... Colin G Miller, PhD, in the firm,s Medical Imaging ...
(Date:5/5/2016)... 2016  Endo International plc (NASDAQ: ... Brian Lortie , President, U.S. Branded Pharmaceuticals, has ... the appointment of a successor. Mr. Lortie joined ... business with responsibility for all strategic, commercial and ... portfolio development, commercial operations, managed markets, manufacturing, supply ...
(Date:5/5/2016)... Grand Cayman , May 5, 2016 Progra ... successful trial of Oxitec , s mosquito ... Aedes aegypti by 96 % ... (MRCU) announced a new plan to fight wild Aedes aegypti, the ... these diseases on the island of Grand Cayman .  MRCU, ...
Breaking Medicine Technology: